Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

89 results about "Antigen delivery" patented technology

Calcium phosphate particles as mucosal adjuvants

The present invention relates to mucosal immune protection, mucosal vaccine delivery, and mucosal drug delivery. Novel calcium phosphate core particles, particularly nanoparticles are used as vaccine adjuvants and compositions for inducing protective mucosal immunity. Methods of inducing an immune response to an antigen by delivering the antigen to a mucosal surface using the particles of this invention, and to methods of making such particles are also provided. The particles of this invention are also useful for delivering compositions, such as a pharmacologically active agent, to the mucosal surfaces of a patient in need thereof, to methods of delivering such compositions, and to methods of making such particles.
Owner:CAPTIVATE PHARMACEUTICALS LLC

Recombinant bacterial vaccine system with environmentally limited viability

Disclosed is an Environmentally Limited Viability System (ELVS) for microorganisms based on temperature differences between permissive and non-permissive environments. Viability of the microorganisms are limited to the permissive environment by specifically expressing one or more essential genes only in the permissive environment, or expressing one or more lethal genes only in the non-permissive environment. Environmentally Limited Viability Systems are also disclosed involving coordinate expression of a combination of required genes and lethal genes. Microorganisms containing an Environmentally Limited Viability System are useful for release into a permissive environment. Temperature regulated Environmentally Limited Viability Systems are particularly suited for use with recombinant avirulent Salmonella vaccines by limiting their growth to the warmer environment inside the host. Such vaccines can be administered to protect humans or warm-blooded animals against bacterial, viral, mycotic and parasitic pathogens, especially those that colonize on or invade through mucosal surfaces. This antigen delivery system can also be used for expression of gamete-specific antigens to induce immune responses to block fertilization, or to induce immune responses to tumor antigens. In the event that an individual sheds live vaccine into the environment, the presence of the ELVS prevents survival of the vaccine. When environmentally regulated lethal genes are present on an extrachromosomal element and are regulated by chromosomal genes, transfer of the extrachromosomal element to other microorganisms will be limited by unregulated expression of the lethal genes in the recipient microorganism.
Owner:WASHINGTON UNIV IN SAINT LOUIS

Antigen delivery vectors and constructs

The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
Owner:ALTIMMUNE UK LTD

Dry formulation for transcutaneous immunization

A transcutaneous immunization system delivers antigen to immune cells through the skin, and induces an immune response in an animal or human. For example, a skin-active adjuvant (e.g., an ADP-ribosylating exotoxin) can be used to induce an antigen-specific immune response (e.g., humoral and / or cellular effectors) after transcutaneous application of a dry formulation containing antigen and adjuvant to skin of the animal or human. The dry formulation may be a powder or a unit-dose patch. Use of adjuvant is not required if the antigen is sufficiently antigenic. Transcutaneous immunization may be induced with or without penetration enhancement.
Owner:IOMAI CORP

Lipid nanoparticle vaccine adjuvants and antigen delivery systems

The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and / or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.
Owner:MERCK SHARP & DOHME LLC

Multiple delivery system for heterologous antigens

The invention is directed to an episomal recombinant nucleic acid encoding at least two heterologous antigens each fused to a PEST-endogenous polypeptide, vaccines comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering the same.
Owner:ADVAXIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products